Honkamp Krueger Financial Services Inc. lifted its position in Emergent Biosolutions Inc (NYSE:EBS) by 25.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,801 shares of the biopharmaceutical company’s stock after acquiring an additional 1,176 shares during the period. Honkamp Krueger Financial Services Inc.’s holdings in Emergent Biosolutions were worth $313,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the company. Evoke Wealth LLC bought a new position in shares of Emergent Biosolutions in the 3rd quarter worth approximately $50,000. Millennium Management LLC bought a new position in shares of Emergent Biosolutions in the 3rd quarter worth approximately $19,579,000. Voloridge Investment Management LLC raised its position in shares of Emergent Biosolutions by 110.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 33,324 shares of the biopharmaceutical company’s stock worth $1,742,000 after acquiring an additional 17,458 shares in the last quarter. Zebra Capital Management LLC bought a new position in shares of Emergent Biosolutions in the 3rd quarter worth approximately $264,000. Finally, Public Employees Retirement System of Ohio raised its position in shares of Emergent Biosolutions by 12.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 46,049 shares of the biopharmaceutical company’s stock worth $2,407,000 after acquiring an additional 5,160 shares in the last quarter. 86.06% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Sue Bailey sold 8,375 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $53.46, for a total transaction of $447,727.50. Following the completion of the transaction, the director now owns 46,333 shares of the company’s stock, valued at approximately $2,476,962.18. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Kathryn C. Zoon sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $54.06, for a total value of $54,060.00. In the last ninety days, insiders have sold 12,457 shares of company stock valued at $668,678. 14.10% of the stock is owned by corporate insiders.
EBS stock opened at $54.96 on Thursday. Emergent Biosolutions Inc has a twelve month low of $39.11 and a twelve month high of $67.45. The company has a quick ratio of 1.71, a current ratio of 2.54 and a debt-to-equity ratio of 0.79. The firm has a market cap of $2.85 billion, a PE ratio of 28.33, a price-to-earnings-growth ratio of 0.77 and a beta of 1.49. The business has a 50 day moving average of $54.26 and a 200 day moving average of $50.67.
Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $1.21 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.58. Emergent Biosolutions had a return on equity of 10.05% and a net margin of 0.42%. The company had revenue of $311.80 million during the quarter, compared to analyst estimates of $289.16 million. During the same quarter last year, the company earned $0.55 EPS. The firm’s revenue for the quarter was up 79.6% on a year-over-year basis. On average, research analysts expect that Emergent Biosolutions Inc will post 3.08 earnings per share for the current fiscal year.
Several research analysts have recently issued reports on EBS shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 target price on shares of Emergent Biosolutions in a research report on Friday, November 22nd. Cowen reissued a “hold” rating and issued a $67.00 target price on shares of Emergent Biosolutions in a research report on Monday, November 25th. Wells Fargo & Co reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Thursday, November 7th. ValuEngine lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Thursday, November 14th. Finally, TheStreet raised Emergent Biosolutions from a “c” rating to a “b” rating in a research report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $69.00.
Emergent Biosolutions Profile
Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids.
Recommended Story: Profit Margin
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.